Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | HRAS inact mut |
| Therapy | Dactolisib |
| Indication/Tumor Type | thyroid cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| HRAS inact mut | thyroid cancer | sensitive | Dactolisib | Preclinical | Actionable | In a preclinical study, BEZ235 inhibited growth of thyroid cancer cells harboring an HRAS pathway activating mutation in cell culture (PMID: 21831957). | 21831957 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (21831957) | Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. | Full reference... |